Literature DB >> 11768331

Resistance of Helicobacter pylori to antibiotics and its impact on treatment options.

F Mégraud1.   

Abstract

The treatment of Helicobacter pylori infection is jeopardized by resistance to the antibiotics used, which turns out to be the main risk factor for failure. Resistance is due to point mutations. For clarithromycin only two sites in the 23S rRNA sequence are concerned and can be easily detected by molecular methods, while for metronidazole several mutations on rdxA and other genes can be responsible and so do not allow such detection. The situation for the rare cases of amoxicillin resistance is not fully determined. The impact of resistance on the clinical outcome is dramatic for clarithromycin while it only decreases the success by 20% for metronidazole.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11768331     DOI： 10.1054/drup.2001.0203

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN： 1368-7646            Impact factor:   18.500


  10 in total

1.  Detection of Helicobacter pylori in paraffin-embedded and in shock-frozen gastric biopsy samples by fluorescent in situ hybridization.

Authors:  Holger Rüssmann; Anne Feydt-Schmidt; Kristin Adler; Daniela Aust; Almuth Fischer; Sibylle Koletzko
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

Review 2.  Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy.

Authors:  Ozlem Yilmaz; Ebru Demiray
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

3.  Azithromycin in one week quadruple therapy for H pylori eradication in Iran.

Authors:  Shahrokh Mousavi; Jafar Toussy; Siamak Yaghmaie; Mehrdad Zahmatkesh
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

4.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: how should rifabutin be managed in rescue regimens?

Authors:  Giuseppe Losurdo; Andrea Iannone; Floriana Giorgio; Mariabeatrice Principi; Alfredo Di Leo; Enzo Ierardi
Journal:  United European Gastroenterol J       Date:  2015-12-15       Impact factor: 4.623

5.  In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole.

Authors:  A Blacky; A Makristathis; P Apfalter; B Willinger; M L Rotter; A M Hirschl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-04       Impact factor: 3.267

6.  Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium.

Authors:  V Y Miendje Deyi; V Y Miendje Deyi; P Bontems; J Vanderpas; E De Koster; R Ntounda; C Van den Borre; S Cadranel; A Burette
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

7.  Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin.

Authors:  Selim Aydemir; Sedat Boyacioglu; Gurden Gur; Muge Demirbilek; Fusun-Kamber Can; Murat Korkmaz; Ugur Yilmaz
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

8.  Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe.

Authors:  S Koletzko; F Richy; P Bontems; J Crone; N Kalach; M L Monteiro; F Gottrand; D Celinska-Cedro; E Roma-Giannikou; G Orderda; S Kolacek; P Urruzuno; M J Martínez-Gómez; T Casswall; M Ashorn; H Bodanszky; F Mégraud
Journal:  Gut       Date:  2006-04-07       Impact factor: 23.059

9.  Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial.

Authors:  A Khoshnood; P Hakimi; H Salman-Roghani; M Reza Mirjalili
Journal:  J Med Life       Date:  2014-06-25

Review 10.  Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection.

Authors:  Nazlı Arslan; Özlem Yılmaz; Ebru Demiray-Gürbüz
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.